Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Cystex Urinary Pain Relief (methenamine / sodium salicylate)
- fecal microbiota spores, live
Interactions between your drugs
methenamine fecal microbiota spores, live
Applies to: Cystex Urinary Pain Relief (methenamine / sodium salicylate), fecal microbiota spores, live
GENERALLY AVOID: Antibiotics may interfere with the therapeutic effects of oral fecal microbiota, which contains live bacterial spores. The mechanism may be related to the antibiotic inactivating the bacterial spores or reducing bacterial replication. However, the clinical significance of this interaction has not been established.
MANAGEMENT: Concomitant use of oral fecal microbiota spores with antibiotics should generally be avoided. The manufacturer of the oral formulation of fecal microbiota recommends that treatment commence two to four days after completing antibiotic treatment for Clostridium difficile infection.
References (1)
- (2023) "Product Information. Vowst (fecal microbiota spores, live)." Aimmune Therapeutics
Drug and food interactions
fecal microbiota spores, live food
Applies to: fecal microbiota spores, live
ADJUST DOSING INTERVAL: There are no data regarding the effects of concurrent administration of oral fecal microbiota spores with food.
MANAGEMENT: The manufacturer of the oral formulation of fecal microbiota recommends that patients should have no food or drink except for a small amount of water for at least 8 hours prior to the first dose of fecal microbiota spores. The second and third doses of fecal microbiota spores should be taken on an empty stomach prior to the first meal of the day.
References (1)
- (2023) "Product Information. Vowst (fecal microbiota spores, live)." Aimmune Therapeutics
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Toviaz
Toviaz (fesoterodine) is used to treat overactive bladder with symptoms of urinary frequency ...
Urispas
Urispas is used for dysuria, urinary frequency, urinary incontinence
Ditropan XL
Ditropan XL is used for dysuria, neurogenic detrusor overactivity, urinary frequency, urinary ...
Botox Cosmetic
Botox Cosmetic is a prescription treatment for fine lines and wrinkles. It temporarily improves the ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.